首页|What do we know about IL-6 in COVID-19 so far?

What do we know about IL-6 in COVID-19 so far?

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
Interleukin 6(IL-6)is a cytokine with dual functions of pro-inflammation and anti-inflammation.It is mainly produced by mononuclear macrophages,Th2 cells,vascular endothelial cells and fibroblasts.IL-6 binds to glycoprotein 130 and one of these two receptors,membrane-bound IL-6R or soluble IL-6R,forming hexamer(IL-6/IL-6R/gp130),which then activates different signaling pathways(classical pathway,trans-signaling pathway)to exert dual immune-modulatory effects of anti-inflammation or pro-inflammation.Abnormal levels of IL-6 can cause multiple pathological reactions,including cy-tokine storm.Related clinical studies have found that IL-6 levels in severe COVID-19 patients were much higher than in healthy population.A large number of studies have shown that IL-6 can trigger a downstream cytokine storm in patients with COVID-19,resulting in lung damages,aggravating clinical symptoms and developing excessive inflammation and acute respiratory distress syndrome(ARDS).Monoclonal antibodies against IL-6 or IL-6R,such as tocilizumab,sarilumab,siltuximab and olokizu-mab may serve as therapeutic options for COVID-19 infection.

IL-6IL-6RCytokine stormCOVID-19Monoclonal antibody

Jingrui Jiang、Jun Wang、Lulu Yao、Shenghan Lai、Xueji Zhang

展开 >

Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China

Department of Biomedicine and Biopharmacology,Hubei University of Technology,Wuhan 430068,China

National 111 Center for Cellular Regulation and Molecular Pharmaceutics,Wuhan 430068,China

Department of Pathology,Johns Hopkins University School of Medicine,MD 21287,USA

Guangdong Laboratory of Artificial Intelligence and Digital Economy(SZ),School of Biomedical Engineering,Shenzhen University,Shenzhen 518037,Guangdong,China

展开 >

2021

生物物理学报
中国生物物理学会 中国科学院生物物理研究所

生物物理学报

影响因子：0.355
ISSN：1000-6737
年,卷(期)：2021.7(3)
  • 138